Reinsurance Group Of America, Incorporated · NYSE:RGA
Reinsurance Group Of America — Investor Presentation (May 2020)
9 slides from Reinsurance Group Of America's investor presentation, May 12, 2020
Slide 1: The COVID-19 Pandemic: Insights and Implications for Insurers
The COVID-19 Pandemic: Insights and Implications for Insurers Hosted by the International Insurance Society and The Institutes Daniel Zimmerman, M.D. Julianne Callaway Tim Rozar 12 May 2020
Slide 2: The Medical View
The Medical View Daniel Zimmerman, M.D. Senior Vice President and Chief Medical Director, Global Support Team
Slide 3: The Medical View
The Medical View ▪ Epidemiology and Trends ▪ Prevention ▪ Clinical Manifestations ▪ Treatment ▪ Recovery and Immunity The COVID-19 Pandemic: Insights and Implications for Insurers 5
Slide 4: Epidemiology and Trends
Epidemiology and Trends Terminology SARS-CoV-2 – the name of the virus 12-18+-month No evidence COVID-19 – the name of the disease timeframe for seasonality caused by the virus ▪ Impact of social distancing COVID-19 – Differing strategies: Sweden Pandemic ▪ Opening-up strategies – Testing and contac
Slide 5: Prevention
Prevention ▪ Masks and face coverings Vaccine update ▪ Social distancing ▪ Leveraging prior research ▪ Accelerating the timeline – ▪ BCG vaccine – protective? collaboration Coalition for Epidemic Preparedness Innovation ▪ Many candidate vaccines ▪ Created in 2017 and strategies* ▪ Stimulate and acce
Slide 6: Clinical Manifestations
Clinical Manifestations Risk factors for Unexpected Rates of hospitalization serious disease consequences increase with age ▪ Age 65 and older ▪ Kidney failure ▪ People in nursing home requiring dialysis Rates of Hospitalization for COVID-19 Increase with age or LTC facility ▪ Cardiac “injury” 20 17
Slide 7: Treatment
Treatment Remdesivir ▪ Use caution when reviewing and Convalescent plasma interpreting results of clinical trials Other antivirals Azithromycin Longer Life Foundation Monoclonal/polyclonal antibodies RGA collaboration with Washington University in St. Louis School of Medicine Hydroxychloroquine and
Slide 8: Recovery and Immunity
Recovery and Immunity A very complex issue… More questions than answers! ▪ What is the correlation between ▪ What if someone has a low or resolution of symptoms and length of undetectable level of antibody? viral shedding? ▪ Is there a risk of reinfection? ▪ Could there be long-term health ▪ What is
Slide 9: ©2020 RGA. All rights reserved. No part of this publication may be reproduced in
©2020 RGA. All rights reserved. No part of this publication may be reproduced in any form without the prior permission of RGA. The information in this publication is for the exclusive, internal use of the recipient and may not be relied upon by any other party other than the recipient and its affili
Reinsurance Group of America — Investor Presentation (May 2020) on 6ix